A Phase II Clinical Trial of SHR-1210 an Anti-PD-1 Inhibitor Simultaneously Combined With Hypofraction Radiotherapy in Patients With Previously Treated Oligometastatic NSCLC
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2018
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2018 Planned End Date changed from 12 Jun 2020 to 9 Jul 2020.
- 19 Jul 2018 Planned primary completion date changed from 12 Jun 2019 to 9 Jul 2019.
- 19 Jul 2018 Status changed from not yet recruiting to recruiting.